: iStockAnalyst.com Symbols Feed

Cancer Vaccines: Investing Opportunities Beyond Dendreon (NASDAQ: DNDN)

Sat, 28 Nov 2009 15:59:46 GMT

Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular immunotherapy approved by the Agency to harness a patient's own immune system in the fight against the disease. Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular[More...]

Diabetes Care: Global Investing Opportunities

Mon, 23 Nov 2009 03:23:59 GMT

The American Diabetes Association estimates that there are currently 23.6 million diabetics in the U.S. (7.8% of the total population, including 17.9 million diagnosed cases, 5.7 million undiagnosed, and 57 million pre-diabetics. Diabetes results in an estimated $174 billion in costs from diagnosed cases of diabetes in the U.S. (2007).[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Tue, 13 Oct 2009 16:29:25 GMT

The BioMedReports.com FDA Calendar database includes over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter (CRL) re-submissions to the FDA; and (4) pending clinical trial results.[More...]

Dendreon (DNDN) Rises As New Board Members Are Appointed

Mon, 12 Oct 2009 18:00:22 GMT

DNDN: Shares of Dendreon (DNDN) traded higher by nearly eight percent during early trading on Monday after it became apparent that the company had recently appointed two new members to its Board of Directors, one being the Chief Executive of Genentech, Ian Clark and the other being Pedro Granadillo, a one time executive for Eli Lilly & Co.[More...]

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

Wed, 07 Oct 2009 19:22:50 GMT

The procedure has been called "one of the most barbaric mistakes ever perpetrated by mainstream medicine." Back when medicine was highly primitive, the process involved shoving an ice pick-like instrument between the upper eyelid and the eye in hopes of severing certain nerves of the frontal lobe.[More...]

SurModics, Inc. (SRDX) Signs Agreement With Genentech and Roche

Wed, 07 Oct 2009 16:22:36 GMT

SurModics, Inc. announced yesterday that it has signed an exclusive agreement with the Roche Group and Genentech for the licensing of its proprietary drug delivery system. This agreement will also establish a development process whereby a new, sustained-delivery formulation for the highly successful Lucentis® (ranibizumab) injection will be commercialized and brought to market using SurModics’ technology, logistics and expertise.[More...]

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Thu, 24 Sep 2009 23:01:08 GMT

On 4/28/09, Dendreon (NASDAQ: DNDN) announced that its experimental cancer vaccine Provenge extended the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option, Taxotere.[More...]

BioMed News Bytes: BSD Medical, Provectus, Incyte, OncoMethylome

Tue, 22 Sep 2009 16:37:17 GMT

On 9/21/09, Provectus Pharma (OTC: PVCT.OB) ($0.96, +1%, above-average volume on 21-Sep) announced that it completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. The primary objective of the Phase 2 study is to investigate the effectiveness of intralesional (IL) PV-10[More...]

Pressure BioSciences (NASDAQ: PBIO): A New Paradigm For Sample Processing

Mon, 21 Sep 2009 03:49:21 GMT

Pressure BioSciences (NASDAQ: PBIO) is a life science research tools company that is commercializing and developing its innovative core technology platform known as pressure cycling technology (PCT). PCT uses cycles of hydrostatic (water-based) pressure between ambient and ultra-high levels (up to 45,000 PSI) at controlled temperatures to rapidly and repeatedly control interactions at the molecular level.[More...]

Thermal technology puts con on hot seat

Tue, 01 Dec 2009 05:48:00 GMT

Dec. 1--Like the Beatles, Suffolk District Attorney Daniel Conley and Boston police have discovered that happiness is a warm gun.
That's because a Dorchester man has become the first defendant convicted of pistol possession by a Massachusetts jury based on thermal imaging evidence.
Giving new meaning to the catchphrase "packing heat," investigators used the technology to successfully link the warmth from 25-year-old Jose Rodrigues' hand to a loaded 9mm Smith & Wesson handgun they found in a snowbank in Dorchester on Jan. 12 as they were chasing him.

: iStockAnalyst.com Symbols Feed

Cancer Vaccines: Investing Opportunities Beyond Dendreon (NASDAQ: DNDN)

Diabetes Care: Global Investing Opportunities

Big Pharma And Biotech - Industry Outlook

FDA Calendar Extreme Trades: 85 Single Digit Stocks

Dendreon (DNDN) Rises As New Board Members Are Appointed

The Next Big Thing In Health Care: How To Profit From Immunotherapy & Regenerative Medicine

SurModics, Inc. (SRDX) Signs Agreement With Genentech and Roche

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

BioMed News Bytes: BSD Medical, Provectus, Incyte, OncoMethylome

Pressure BioSciences (NASDAQ: PBIO): A New Paradigm For Sample Processing

Thermal technology puts con on hot seat

Fewer new jobs in county in the third quarter

Rare plant thought to be discovered near Doyle Drive project

Qiagen acquires SABiosciences

Jury convicts N.J. man of southside Lebanon bank robbery

Carnegie Mellon exhibit blurs line between artist, tools

The News and Advance, Lynchburg, Va., Darrell Laurant Column: A Problem That Needs to Be Addressed

Catch Up on Tribune Watchdog Reporting: 10 Reports That Got Results

MandT Reports 41% Increase in Profits for Third Quarter

MandTreports 41% Increase in Profits for Third Quarter

Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market

FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)

Roche Completes Acquisition of Genentech

Roche Completes Tender Offer for Genentech

Zacks Analyst Blog Highlights: Vivo Participacoes, America Movil, TIM Participacoes, Amylin Pharmaceuticals, Inc. And Eli Lilly.

Capacity Crowd at 2009 Southeast Venture Conference Optimistic About Market - Mar 19 2009 6:53PM

Capacity Crowd at 2009 Southeast Venture Conference Optimistic About Market - Mar 19 2009 2:52PM

OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer

Zacks Industry Outlook Highlights: Roche, Genentech, Gilead Sciences and CV Therapeutics

Over 80 Life Science Industry Exhibitors at the NYBA Annual Meeting

Form 4 Yang Patrick Y For: Mar 26 (10K)

Form 4 Andreatta Robert E For: Mar 26 (10K)

Form 4 CLARK IAN T For: Mar 26 (10K)

Form 4 GENENTECH INC For: Mar 26 Filed by: SANDERS CHARLES A (10K)

Form 4 BOYER HERBERT W PH D For: Mar 26 (10K)

Form 4 REED DEBRA L For: Mar 26 (10K)

Form 4 EBERSMAN DAVID A For: Mar 26 (10K)

Form 4 LEVINSON ARTHUR D For: Mar 26 (10K)

Form 4 DESMOND HELLMANN SUSAN For: Mar 26 (10K)

Form 4 SCHELLER RICHARD H For: Mar 26 (10K)